



(12) **United States Patent**  
**Kim et al.**

(10) **Patent No.: US 6,284,727 B1**  
(45) **Date of Patent: Sep. 4, 2001**

(54) **PROLONGED DELIVERY OF PEPTIDES**

(75) Inventors: **Yesook Kim; William J. Lambert; Hong Qi; Robert A Gelfand; Kieran F. Geoghegan; Dennis E. Danley**, all of New York, NY (US)

(73) Assignee: **Scios, Inc.**, Sunnyvale, CA (US)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **08/472,349**

(22) Filed: **Jun. 7, 1995**

**Related U.S. Application Data**

(63) Continuation of application No. 08/181,655, filed on Jan. 25, 1994, now abandoned, which is a continuation-in-part of application No. 08/044,133, filed on Apr. 7, 1993, now abandoned.

(51) **Int. Cl.<sup>7</sup>** ..... **A61K 38/00**  
(52) **U.S. Cl.** ..... **514/12; 530/324**  
(58) **Field of Search** ..... **514/12; 530/324**

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

4,654,324	*	3/1987	Chance et al.	514/12
4,857,505	*	8/1989	Ardent	514/2
4,985,404	*	1/1991	Mitchell	514/6
5,118,666	*	6/1992	Habener	514/12
5,120,712	*	6/1992	Habener	514/12
5,175,145	*	12/1992	Cooper	514/4
5,424,286		6/1995	Eng	514/2
5,545,618		8/1996	Buckley et al.	514/2
5,574,008		11/1996	Johnson et al.	514/12
5,614,492		3/1997	Habener	514/12
5,631,224		5/1997	Efendic	514/12

**FOREIGN PATENT DOCUMENTS**

19530865	A1	2/1997	(DE)	
0 177 478		4/1986	(EP)	
0 343 696	A2	11/1989	(EP)	
0 442 671	A2	8/1991	(EP)	
0 473 268	A3	3/1992	(EP)	
0 526 862	A1	2/1993	(EP)	
0 619 322	A2	10/1994	(EP)	
0 658 568	A1	6/1995	(EP)	
0 733 644	A1	9/1996	(EP)	
2 732 894		10/1996	(FR)	
06941	*	11/1987	(WO)	C07K/7/10
WO 88/07366		10/1988	(WO)	
WO 90/02835		3/1990	(WO)	
11296	*	10/1990	(WO)	C07K/7/10
11457	*	8/1991	(WO)	C07K/7/34
WO 93/18785		9/1993	(WO)	
WO 93/18786		9/1993	(WO)	
WO 93/19175		9/1993	(WO)	
WO 93/25579		12/1993	(WO)	
WO 95/05848		3/1995	(WO)	
WO 95/07098		3/1995	(WO)	
WO 95/17510		6/1995	(WO)	
WO 95/31214		11/1995	(WO)	

**OTHER PUBLICATIONS**

Kreymann et al, Laneef Dec. 5, 1987 p. 1300.\*  
 Conn's Current Therapy p. 483. (1989).\*  
 Remington's Pharmaceutical Sciences, 16th ed. p. 1555, 1467, 1453, 1451, 1450, 1448, CH 91, 1980.\*  
 Cross et al., "Subcutaneous Absorption Kinetics And Local Tissue Distribution Of Interferon And Other Solutes," J. Pharm. Pharmacol., 1993, 45, pp. 606-609.  
 Hirano et al., "Studies on the Absorption of Practically Water-Insoluble Drugs Following Injection VIII: Comparison of the Subcutaneous Absorption Rates From Aqueous Suspensions in the Mouse, Rat and Rabbit," J. Pharm. Sci., 1993, 72(6), pp. 608-612.  
 Nara et al., "A New Method for Assessment of Drug Absorption From Muscle: Application of a Local Perfusion System," J. Pharm. Pharmacol, 1991, 43, pp. 272-274.  
 Dickert et al., "Absorption of NPH-Insulin from Subcutaneous Tissue: A Methodological Study in Pigs," ACTA Pharmacol et Toxicol, 1982, 51, pp. 30-37.  
 Supersaxo et al., "Effects of Molecular Weight on the Lymphatic Absorption of Water-Soluble Compounds Following Subcutaneous Administration," Pharmaceutical Research, 1990, 7(2), pp. 167-169.  
 Mosjov, "Structural Requirements for Biological Activity of Glucagon-Like Peptide-1, " Int. J. Peptide Protein Res., 1992, 40, pp. 333-343.  
 Suzuki et al., "Comparison of the Effects of Various C-Terminal and N-Terminal Fragment Peptide of Glucogen-Like Peptide-1 or Insulin and Glucagon Release from the Isolated Perfused Rat Pancreas," Endocrinology, 1989, 125(6), pp. 3109-3113.  
 Krówczyński, Leszek, "Technologia postaci leków (Technology of the drug forms)", Państwowy Zakład Wydawnictw Lekarskich Warszawa, 1969, pp. 220, 463-464, 490, 502.  
 Gennaro, Alfonso R., Chapter 23 in Remington's Pharmaceutical Sciences, 16th edition, A. Osol Editor, Mack Publishing Company, Easton, PA, 1980, pp. 343-363.  
 Gill, I. J. et al., "Cyclodextrins as protection agents against enhancer damage in nasal delivery systems II. Effect on in vivo absorption of insulin and histopathology of nasal membrane," *European Journal of Pharmaceutical Sciences* 1:237-248, Jun. 1994.  
 Hendrick, G.K. et al., "Glucagon-like Peptide-I-(7-37) Suppresses Hyperglycemia in Rats," *Metabolism* 42(1):1-6, Jan. 1993.

(List continued on next page.)

*Primary Examiner*—Sheela Huff  
(74) *Attorney, Agent, or Firm*—Sterne, Kessler, Goldstein & Fox P.L.L.C.

(57) **ABSTRACT**

There are disclosed methods for the treatment of non-insulin dependent diabetes mellitus in a mammal comprising the prolonged administration of GLP-1 (7-37), and related peptides. Also disclosed are compositions to prolong the administration of the peptides.

## OTHER PUBLICATIONS

- Holst, J.J. et al., "Truncated glucago-like peptide I, an insulin-releasing hormone for the distal gut," *FEBS Letters* 211(2):169-174, Jan. 1987.
- Remington'Pharmaceutical Sciences, 16th ed. pp. 1555, 1467, 1453, 1451, 1450, 1448, Ch. 91, 1980.\*
- Cross et al., "Subcutaneous Absorption Kinetics and Local Tissue Distribution of Interferon and other Soluter," *J. Pharm. Pharmacol.*, 1993, 45, pp. 606-609;.
- Hirano et al., "Studies on the Absorption of Practically Water-Insoluble Drugs following Injection VIII: Comparison of the Subcutaneous Absorption Rates from Aqueous Suspensions in the Mouse, Rat, and Rabbit," *J. Pharm. Sci.*, 1993, 72(6), pp. 608-612;.
- Nara et al., "A New Method for Assessment of Drug Absorption from Muscle: Application of a Local Perfusion System," *J. Pharm. Pharmacol.*, 1991, 43, pp. 272-274;.
- Dickert et al., "Absorption of NPH-Insulin from Subcutaneous Tissue: A Methodological Study in Pigs," *Acta Pharmacol et Toxicol*, 1982, 51, pp. 30-37;.
- Supersaxo et al., "Effects of Molecular Weight on the Lymphatic Absorption of Water-Soluble Compounds following Subcutaneous Administration," *Pharmaceutical Research*, 1990, 7(2), pp. 167-169;.
- Mosjov, "Structural requiremnts for Biological Activity of Glucagon-like Peptide-1," *Int. J. Peptide Protein Res.*, 1992, 40, pp. 333-343;.
- Suzuki et al., "Comparison of the Effects of various C-Terminal and N-Terminal Fragment Peptide of Glucogen-like Peptide-1 or Insulin and Glucagon Release from the Isolated Perfused Rat Pancreas," *endocrinology*, 1989, 125(6), pp. 3109-3113.

\* cited by examiner

FIG. 1




FIG. 2





FIG. 3



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.